To proceed to the next module, CLICK HERE

  
Chairperson 
 
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

Dr. Mark A. Socinski is Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh in Pittsburgh, Pennsylvania. Board certified in internal medicine and medical oncology, he also is Co-Director of the University of Pittsburgh Medical Center’s Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence (SPORE) in Lung Cancer. Dr. Socinski is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has authored many manuscripts principally in thoracic oncology. 

Dr. Socinski received a Master of Science degree in Pathology and a Doctor of Medicine degree from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School Beth Israel Hospital in Boston. He went on to complete medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute. 

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers’ bureau: Celgene Corporation; Genentech, Inc.; Contracted research: Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; GlaxoSmithKline; Pfizer, Inc.; PUMA Biotechnology; Synta Pharmaceuticals Corp. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS; Deborah Middleton, MS; and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Faculty 
 
 
Christopher G. Azzoli, MD 
Assistant in Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Visiting Assistant Professor
Harvard Medical School
Boston, Massachusetts

 

Christopher G. Azzoli, MD, currently serves as Assistant in Medicine at the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, and Visiting Assistant Professor at Harvard Medical School. He previously served as faculty at Memorial Sloan Kettering Cancer Center in New York, New York, where he was five-time winner of the annual Fellowship Teaching Award. Dr. Azzoli has authored, or coauthored, clinical practice guidelines from the American Society of Clinical Oncology (ASCO) for chemotherapy for early stage, and stage IV non–small cell lung cancer. Based on this service, he was appointed Chair of the ASCO Clinical Practice Guideline Committee in 2012. His research interests include the development of novel chemotherapy for patients with non–small cell lung cancer, with special interest in combined modality therapy for early stage disease, and the development of blood biomarkers to guide therapy.
 
Dr. Azzoli earned a Doctor of Medicine degree from Johns Hopkins University in Baltimore, Maryland, where he also completed his residency training in internal medicine. He then completed a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. 

Christopher G. Azzoli, MD, has no real or apparent conflicts of interest to report.


 
 
Jeffrey Crawford, MD 
George Barth Geller Professor for Research in Cancer
Duke University Medical Center
Co-Director of the Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina 

Jeffrey Crawford, MD, is George Barth Geller Professor for Research in Cancer and Duke University Medical Center and Co-Director of the Solid Tumor Therapeutics Program in the Duke Cancer Institute in Durham, North Carolina. Board certified in internal medicine, hematology, and oncology. Dr. Crawford served as Chief of the Division of Medical Oncology for 10 years prior to assuming his current leadership roles. 

Dr. Crawford’s research interests include new treatment approaches to lung cancer, supportive care therapies, and clinical trials of hematopoietic growth factors, biological agents, and targeted drug development. He has published more than 180 manuscripts and chapters. Dr. Crawford is Principal Investigator for the National Clinical Trials Network Lead Academic Site Grant at Duke. He is also a Vice-Chair for the Respiratory Cancer Committee for the Alliance and Chair of National Comprehensive Cancer Network’s Myeloid Growth Factors Panel. Dr. Crawford earned a Doctor of Medicine degree from Ohio State University and completed an internship, residency, and hematology/oncology fellowship at Duke University Medical Center. He also completed a fellowship in geriatrics at Veterans Administration Medical Center in Durham, North Carolina. 

Jeffrey Crawford, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards: Bayer Pharmaceuticals Corporation; Boehringer Ingelheim; Eli Lilly and Company; Gilead, Hospira, Inc.; ONO Pharmaceutical Co. LTD; Data and safety monitoring board member: Celgene Corporation; Hoffmann-La Roche Inc.; Merrimack Pharmaceuticals; sanofi US; Principal investigator/research funding: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; GTx; MedImmune (AstraZeneca).


 

 
David S. Ettinger, MD, FACP, FCCP 
Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Johns Hopkins University School of Medicine
Baltimore, Maryland 

David S. Ettinger, MD, is the Alex Grass Professor of Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also a Professor of Medicine of otolaryngology, head and neck surgery, gynecology and obstetrics, radiation oncology, and molecular radiation sciences. Dr. Ettinger’s research interests are in new drug development and innovative multidisciplinary treatment strategies in lung cancer and sarcomas. He is also interested in improving supportive care measures associated with cancer and its treatment. Dr. Ettinger has authored or coauthored over 200 articles and serves as an Editor for Current Treatment Options in Oncology. He has edited three books: Thoracic Oncology, Kluwer Academic Publishers, 2001; Current Cancer Therapeutics, 5th Edition, Springer, 2009; and Supportive Care in Cancer Therapy, Humana Press, 2009. 

Dr. Ettinger is a member of the board of directors of the National Comprehensive Cancer Network® (NCCN®) as well as a member of the NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®) Steering Committee. In addition, he has been Chairman of the NCCN Guidelines® panels for non–small cell lung cancer practice, antiemetic practice, and occult primary tumor practice.  Dr. Ettinger has presented the NCCN Guidelines® for non–small cell lung cancer in China, the Middle East, and Brazil, and has assessed research opportunities in China. From 1982 through 1990, he was Principal Investigator of phase 1 studies of new anticancer agents, sponsored by the National Institutes of Health. Dr. Ettinger received a Doctor of Medicine degree from the University of Louisville in Kentucky. He completed a medical internship and residency at the Albany Medical Center and Mayo Clinic, respectively. 

David S. Ettinger, MD, FACP, FCCP, reported a financial interest/relationship or affiliation in the form of Consulting fee: AMAG Pharmaceuticals; Ariad Pharmaceuticals, Inc.; Biodesix, Inc.; Boehringer Ingelheim; Eisai Inc.; Eli Lilly and Company; Gilead; Genentech - A member of the Roche Group, Helsinn.
 


 
Roy S. Herbst, MD, PhD 
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director of the Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut 

Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Comprehensive Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr. Herbst has led the phase 1 development of several of the new generation of targeted agents for non–small cell lung cancer, including gefitinib, erlotinib, cetuximab, and bevacizumab. He is Co-Lead for the BATTLE-1 effort, the subsequent BATTLE-2 clinical trial program, and serves as a Co-Program Leader of the Developmental Therapeutics Program for the Yale Comprehensive Cancer Center support grant. He is a member of the National Cancer Policy Forum, for which he has organized an Institutes of Medicine meeting focused on policy issues in personalized medicine. His laboratory work is focused on angiogenesis and dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibition in non–small cell lung cancer. 

Dr. Herbst is author and coauthor of more than 250 publications, including peer-reviewed journal articles, abstracts, and book chapters. He has contributed his work to many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and The New England Journal of Medicine. Dr. Herbst is an active member of American Society of Clinical Oncology, American Association for Cancer Research, International Association for the Study of Lung Cancer, Radiation Therapy Oncology Group, and Southwest Oncology Group Lung Committee.  He received a Doctor of Medicine degree from Cornell University Medical College and a Doctorate in Molecular Cell Biology from Rockefeller University in New York, New York. 

Roy S. Herbst, MD, PhD, reported a financial interest/relationship or affiliation in the form of Scientific advisory board: Biothera; Diatech Oncology; Kolltan Pharmaceuticals, Inc.; N-of-One; NovaRx Corporation; Consultant: Eli Lilly and Company; Genentech - A member of the Roche Group; Merck & Co., Inc.; Pfizer, Inc.; Clinical trial support/grant: Genentech, Inc.
 


 
Karen L. Reckamp, MD, MS 
Associate Professor
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, California 

Karen Reckamp, MD, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. Her activities at City of Hope include Medical Director of the Thoracic Oncology program and Chair of the City of Hope Comprehensive Cancer Center scientific review committee. She is a member of the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology committees on lung cancer, thymic malignancies, and mesothelioma. She serves as Principal Investigator for many phase 1 and 2 studies funded by organizations such as the National Cancer Institute. 

Dr. Reckamp is a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research, American Association for the Advancement of Science, International Association for the Study of Lung Cancer, and Southwest Oncology Group. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. She has also authored and coauthored many manuscripts in thoracic oncology. Dr. Reckamp received a Doctor of Medicine degree from the University of Chicago, and a Master of Science degree in Clinical Investigation from the University of California, Los Angeles. She completed residency training in internal medicine at Barnes-Jewish Hospital, and a hematology/ oncology fellowship at the David Geffen School of Medicine at University of California, Los Angeles. 

Karen L. Reckamp, MD, MS, reported a financial interest/relationship or affiliation in the form of Advisory board: Amgen, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Contracted research: Ariad Pharmaceuticals, Inc.; Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer, Inc.
 


 
Joan H. Schiller, MD 
Deputy Director Simmons Cancer Center
Chief, Hematology/Oncology
University of Texas-Southwestern
President, Free to Breathe
Dallas, Texas 

Joan H. Schiller, MD, is Deputy Director of Simmons Comprehensive Cancer Center, holds the Andrea L. Simmons Distinguished Chair in Cancer Research, and is Division Chief of Hematology/Oncology at the University of Texas-Southwestern Medical Center in Dallas. She is also Founder and President of Free to Breathe, a national advocacy organization aimed at raising awareness and funding for lung cancer. Free to Breathe has awarded over $4 million dollars in research funds to close to 50 investigators since 2005. 

Dr. Schiller is internationally recognized for her work in lung cancer clinical research. Dr. Schiller’s research has generated well over 200 publications that she has authored or coauthored, including articles, abstracts, book chapters, books, reviews and invited manuscripts. She has served as an Editor for the Journal of Clinical Oncology, and was a Board Member for the International Association for the Study of Lung Cancer, and a Principal Investigator on many national clinical trials for lung cancer. She also served as Chairperson of the Thoracic Oncology Committee of the Eastern Cooperative Oncology Group for many years until stepping down from that position in 2012.
 
Dr. Schiller received a Doctor of Medicine degree from the University of Illinois and completed an internship and residency in internal medicine at Northwestern Memorial Hospital in Chicago. She then completed a clinical fellowship at the University of Wisconsin Comprehensive Cancer Center. 

Joan H. Schiller, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee: AVEO Pharmaceuticals, Inc.; Biodesix, Inc.; Clovis Oncology; Eli Lilly and Company; Merck & Co., Inc.; Contracted research: AbbVie; Astex Pharmaceuticals Inc.; Clovis Oncology; Genentech, Inc.; Pfizer, Inc.; PUMA Biotechnology; Synta Pharmaceuticals Corp.
 


 
 
Lecia V. Sequist, MD, MPH 
Associate Professor of Medicine\
Harvard Medical School
Mary B. Saltonstall Endowed Chair in Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

 

Dr. Lecia V. Sequist is currently Associate Professor of Medicine at Harvard Medical School and the Mary B. Saltonstall Endowed Chair in Medical Oncology at Massachusetts General Hospital in Boston. Her research focuses on studying novel targets for lung cancer treatment, especially in patients with epidermal growth factor receptor mutations and other driver oncogenes. She also studies the changes that occur in cancers at the time of acquired drug resistance and the significance of circulating tumor cells. Dr. Sequist seeks to develop treatment algorithms for lung cancer that are more personalized than current strategies, using targeted therapies specific to the patients’ cancer genotypes, and understanding how this may change over the course of the disease. 

Dr. Sequist received a Doctor of Medicine degree from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received a Master of Science degree in Public Health from Harvard University. 

Lecia V. Sequist, MD, MPH, reported a financial interest/relationship or affiliation in the form of Uncompensated consulting relationship: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Merrimack Pharmaceuticals; Novartis Pharmaceuticals Corporation; Taiho Pharmaceutical Co., Ltd.
 


 
 
 
George R. Simon, MD, FACP, FCCP 
Professor of Medicine & Oncology
Section Chief for Translational Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

 

Dr. George R. Simon, is Professor of Medicine and Oncology and Section Chief for Translational Research, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center in Houston. Previously, he held the Burtschy Family Distinguished Endowed Chair in Cancer Research at the Medical University of South Carolina in Charleston. Dr. Simon was also a member of a team of physicians who competed successfully for a Lung Cancer Specialized Program of Research Excellence award. His research interests include DNA repair, tumor metabolism, and epigenetic modulation of cancer and targeting these for therapeutic gain. He has also authored or coauthored more than 80 peer-reviewed publications. 

A Fellow of the American College of Physicians and the American College of Chest Physicians, Dr. Simon is a member of several professional organizations, including the American Society of Clinical Oncology, American Association for Cancer Research, American Association for the Advancement of Science, and International Association for the Study of Lung Cancer. He has also received research funding from the National Cancer Institute and the Department of Defense.  Dr. Simon has served as a reviewer on numerous national and international panels. He has also served as a panel member of the American College of Chest Physicians and the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology® on lung cancer. 

Dr. Simon received a Doctor of Medicine degree from Christian Medical College and Hospital in Ludhiana, Punjab India, where he also completed a residency in internal medicine. He completed a medical oncology and hematology fellowship at the University of Colorado Health Sciences Center in Denver. 

George R. Simon, MD, FACP, FCCP, reported a financial interest/relationship or affiliation in the form of Advisory board: Boehringer Ingelheim; Celgene Corporation; Genentech, Inc.; Speakers’ bureau: Genentech, Inc.; Contracted research: Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company.
 


 
 
 
 
Thomas E. Stinchcombe, MD
Associate Professor Internal Medicine
Director of the Thoracic Oncology Program
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina  Texas MD Anderson Cancer Center
Houston, Texas

 

Dr. Thomas E. Stinchcombe is Associate Professor in the Department of Internal Medicine, a member of Lineberger Comprehensive Cancer Center, and Director of Thoracic Oncology Program at the University of North Carolina in Chapel Hill. His clinical interest lies in thoracic malignancies with research focusing on clinical trials in non– small cell and small cell lung cancer. Dr. Stinchcombe is a member of the Respiratory Committee of the Alliance Cooperative Trials Group. He received a Doctor of Medicine degree from the University of Virginia in Charlottesville, and completed an internal medicine residency at the University of Michigan in Ann Arbor and a hematology and oncology fellowship at the University of North Carolina. 

Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers’ bureau: Celgene Corporation; Genentech, Inc.; Contracted research: Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; GlaxoSmithKline; Pfizer, Inc.; PUMA Biotechnology; Synta Pharmaceuticals Corp.
 


 
 
 
 
 
Heather Wakelee, MD 
Associate Professor, Department of Medicine
Stanford University Advanced Medical Center\
Faculty Director
Stanford University Cancer Clinical Trials Office
Stanford, California 

 

Heather Wakelee, MD, is Associate Professor of Medicine at Stanford University in the Division of Oncology, where she leads the thoracic medical oncology research program and has authored and coauthored over 100 medical articles on thoracic malignancies. She is Faculty Director of the Stanford University Cancer Clinical Trials office. Dr. Wakelee’s clinical research interest is in thoracic malignancies including lung cancer and thymic malignancies with particular interest in never-smokers and novel lung cancer biomarkers. Dr. Wakelee has led multiple investigator-initiated protocols and played a central role in clinical trials with bevacizumab and many other antiangiogenic agents. She is the Principal Investigator on the multinational E1505 study of adjuvant bevacizumab in non–small cell lung cancer. Dr. Wakelee has also led clinical trials of drugs and drug combinations comprised of epidermal growth factor receptor, alanine aminotransferase, and Met inhibition, as well as novel immunotherapeutics. She is an active member of the Eastern Cooperative Oncology Group, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, and the International Thymic Malignancies Interest Group.

Dr. Wakelee received a Doctor of Medicine degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She then completed an internal medicine residency and a medical oncology fellowship at Stanford. 

Heather Wakelee, MD, reported a financial interest/relationship or affiliation in the form of Speakers’ bureau: Peregrine Pharmaceuticals, Inc.; Contracted research, AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb/Exelixis Inc.; Celgene Corporation; Clovis Oncology; Genentech- A member of the Roche Group; Lilly USA; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Xcovery.

To proceed to the next module, CLICK HERE